The research, led by Oğuzhan Türksayar of Başakşehir Çam and Sakura City Hospital in Istanbul and colleagues at institutions across Türkiye, focused on 17 brain metastases treated in 12 consecutive patients who received single-session Gamma Knife radiosurgery. Each patient underwent dynamic contrast-enhanced MRI before treatment and again at the four-to-eight-week mark. Rather than simply observing whether lesions shrank, the team used pharmacokinetic modeling to quantify how the blood-brain barrier and tumor vasculature were behaving, extracting parameters that reflect the movement of contrast agent between blood vessels and tumor tissue.

The technical core of the study lies in the Tofts pharmacokinetic model, a mathematical framework that describes how gadolinium-based contrast material leaks from blood plasma into the extravascular extracellular space of tissue. From this model, the researchers derived several quantitative parameters. The volume transfer constant, known as Ktrans, measures how quickly contrast crosses from the vascular compartment into tissue, serving as a proxy for vascular permeability and blood flow. Kep, the rate constant, describes how rapidly contrast returns from tissue back to the plasma, while Ve represents the fraction of tissue volume occupied by the extravascular extracellular space. The team also measured the initial area under the concentration-time curve, or iAUC, a semiquantitative indicator of early contrast enhancement that captures the first blush of agent entering the lesion.

In addition to these model-based parameters, the researchers extracted semiquantitative features directly from the signal-intensity curves generated during the dynamic scan, including the upslope and the initial gradient of enhancement. These metrics do not require pharmacokinetic assumptions, making them quicker to compute, but they are also more sensitive to variations in scanning protocol. By combining both approaches, the study aimed to determine which measurements best captured the biological consequences of radiation in the earliest phase of treatment.

The results showed a consistent pattern. After radiosurgery, Ktrans, Kep, and iAUC all decreased significantly across the treated lesions, and these reductions remained statistically meaningful even after the researchers applied Benjamini-Hochberg false discovery rate correction, a conservative statistical adjustment designed to guard against false positives when many comparisons are made. The initial gradient also decreased in unadjusted analysis, but this finding did not survive correction. In practical terms, the tumors’ permeability-surface characteristics declined measurably within weeks of treatment, suggesting that radiosurgery was already altering the abnormal vasculature that sustains metastatic growth.

Response classification followed the RANO-BM criteria, the standardized framework developed by the Response Assessment in Neuro-Oncology working group for evaluating brain metastases. Of the 17 lesions, six, representing 35.3 percent, were classified as partial response, while eleven, or 64.7 percent, showed stable disease. Notably, no lesion progressed during this early window, and none achieved complete response, which is typical at such an early checkpoint since tumor shrinkage lags behind vascular change.

The most provocative finding emerged when the researchers examined whether the magnitude of imaging change tracked with the degree of response. In unadjusted analyses, the percentage change in Ktrans was associated with concurrent early radiologic response, with a Spearman correlation coefficient of negative 0.553, and the percentage change in upslope showed a similar association with a coefficient of negative 0.503. Lesions classified as partial response also showed a greater absolute reduction in Ktrans than stable-disease lesions before correction for multiple comparisons. However, the authors are careful to note that none of these between-group or correlation findings survived false discovery rate correction, a caveat that colors the entire study’s conclusions.

This statistical honesty is a defining feature of the work. The researchers label their findings as hypothesis-generating and explicitly state that they require validation in larger, adequately powered, and methodologically standardized cohorts before any clinical application. Recognizing that their small sample involved multiple lesions per patient, which can inflate statistical confidence, they performed a sensitivity analysis using only one lesion per patient. The direction of the Ktrans difference remained consistent with the lesion-level analysis, offering some reassurance that the signal, while not statistically robust in a sample of this size, was not an artifact of clustering within individual patients.

The implications, if confirmed, could be substantial. Early identification of nonresponding lesions would allow oncologists to adjust treatment sooner, whether by adding systemic therapy, planning repeat radiosurgery, or intensifying surveillance, rather than waiting months for conventional scans to reveal failure. Dynamic contrast-enhanced MRI is already available on most modern clinical scanners and can be added to routine follow-up protocols, though its pharmacokinetic modeling demands careful attention to acquisition parameters. The prospective design of this study, with baseline and early post-treatment imaging performed under controlled conditions, strengthens its foundation compared with retrospective analyses, and the lesion-level approach provides fine-grained detail about how individual metastases behave rather than averaging across patients.

For now, the study stands as an early but carefully executed proof of concept. Brain metastases affect a large proportion of patients with advanced cancer, and stereotactic radiosurgery is one of the most common treatments delivered to them, making any tool that accelerates response assessment clinically valuable. The Turkish team’s work demonstrates that measurable vascular changes appear within four to eight weeks of Gamma Knife treatment and that Ktrans, the volume transfer constant, was the most consistent parameter associated with early radiologic response in unadjusted analyses. The road from exploratory association to clinical decision-making runs through larger, standardized, multi-center trials, but this study charts a plausible path toward a future in which the effectiveness of radiation against brain tumors can be read not just in their size, but in the chemistry of their blood vessels.

Subject of Research: Early dynamic contrast-enhanced MRI biomarkers of radiologic response after stereotactic radiosurgery for brain metastases

Article Title: Early DCE-MRI changes and concurrent radiologic response after stereotactic radiosurgery for brain metastases: a prospective exploratory study

Article References: Türksayar, O., Öner, A. Y., Cindil, E., Erpolat, P., & Emmez, H. (2026). Early DCE-MRI changes and concurrent radiologic response after stereotactic radiosurgery for brain metastases: a prospective exploratory study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02756-8

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02756-8

Keywords: DCE-MRI, stereotactic radiosurgery, brain metastases, Ktrans, Tofts pharmacokinetic model, Gamma Knife, RANO-BM criteria, treatment response assessment, blood-brain barrier, MRI biomarkers, false discovery rate, radiation oncology

The technique at the heart of the study is called habitat imaging, and it represents a fundamental shift in how radiologists look at tumors. Instead of treating a tumor as a single lump to be measured with a ruler, habitat imaging divides it into biologically distinct subregions, or habitats, based on the functional characteristics of each voxel, the tiny three-dimensional pixels that make up the scan. The researchers used dynamic contrast-enhanced MRI, or DCE-MRI, which tracks the passage of a gadolinium contrast agent through tissue in real time. By fitting the resulting signal curves to a mathematical framework known as the Tofts model, they extracted pharmacokinetic parameters that describe the tumor’s microvasculature: Ktrans, which reflects the transfer of contrast from blood plasma into tissue; Ve, the volume of the extracellular space; and Kep, the rate at which contrast returns to the blood.

These parameters are not just numbers on a screen. They encode the biology of the tumor microenvironment. A region with high Ktrans is densely vascularized and leaky, often a sign of aggressive growth and abundant blood supply. A region with high Ve may indicate necrosis, edema, or expanded extracellular matrix, all of which can follow effective treatment. When radiation and targeted therapy attack a tumor, they strike these microenvironmental compartments unevenly. Some pockets of cancer cells die quickly as their blood supply collapses; others, perhaps better oxygenated or genetically hardier, survive. Conventional MRI and the widely used RECIST 1.1 criteria, which simply measure the longest diameter of the tumor, are blind to this internal heterogeneity. A tumor can be riddled with dead tissue yet still measure the same size on a standard scan.

To test whether habitat imaging could capture these early changes, the team prospectively enrolled 28 patients with soft tissue sarcoma who were undergoing protocol-specified neoadjuvant radiotherapy-based treatment, an approach combining radiation with targeted therapy. The study was conducted under two prospectively registered clinical trials, NCT05167994 and NCT05938374, and all participants gave written informed consent. Each patient underwent DCE-MRI twice: once at baseline before treatment began, and again six weeks into therapy. After the tumors were surgically removed, an experienced sarcoma pathologist examined the resected specimens and determined the percentage of viable residual tumor cells, the gold-standard measure of how well the treatment had worked.

The pathological results underscored just how difficult this disease is to treat. Only 5 of the 28 patients, or 17.9 percent, achieved a favorable response, defined as 5 percent or fewer viable tumor cells remaining in the surgical specimen. The remaining patients had substantial amounts of surviving cancer despite weeks of radiation and targeted therapy. This imbalance, with so few responders, is itself a reminder of why early prediction matters: if clinicians could identify non-responders early, they might intensify treatment, switch strategies, or spare patients the toxicities of a regimen that is not working.

The imaging analysis began with K-means clustering, an unsupervised machine learning algorithm that groups voxels according to their Ktrans and Ve values. This partitioned each tumor into distinct habitats representing different vascular and tissue microenvironments. The researchers then extracted radiomic features, quantitative descriptors of shape, intensity, and texture, from both the whole tumor and the individual habitat subregions. They also computed delta radiomics features, calculated as the difference between pre-treatment and post-treatment values, capturing how each feature changed over the course of therapy. After univariate analysis identified seven features associated with treatment response, the team built three logistic regression models using Akaike information criterion-based bidirectional selection: a Whole-tumor model, a Habitat model, and a Delta model.

The results were striking, though the researchers are careful to frame them as preliminary. All habitat subregions showed significant volumetric reduction after therapy, with all P values below 0.05, although the proportional shrinkage did not differ significantly among subregions. The standout performer was the Habitat model, which combined two features: pre-treatment Ktrans cluster-1 kurtosis, a measure of how peaked the distribution of vascular permeability values was before treatment, and post-treatment Kep cluster-3 uniformity, which describes how homogeneous the contrast washout rate became in one habitat after therapy. This model achieved an area under the receiver operating characteristic curve of 0.887, with 100 percent sensitivity and 73.9 percent specificity in the apparent analysis. In other words, it caught every true responder while misclassifying roughly a quarter of non-responders as responders.

Bootstrap internal validation tempered the enthusiasm somewhat. After correcting for optimism, the AUC dropped to 0.764, and the corrected discrimination was comparable across the three radiomics-based models. This kind of shrinkage is expected in small studies and is precisely why the authors describe their findings as exploratory. Still, the Habitat model showed favorable calibration, with a Hosmer-Lemeshow P value of 0.973, meaning its predicted probabilities aligned well with observed outcomes, and decision curve analysis suggested potential clinical utility. Perhaps most telling was the comparison with the current standard of care. RECIST 1.1, evaluated as a fixed categorical reference, achieved only 40 percent sensitivity, 82.6 percent specificity, and 75 percent accuracy against the pathological endpoint. The conventional method missed more than half of the patients whose tumors had actually responded, while the habitat-based model caught all of them.

The clinical implications of this work extend well beyond sarcoma. Neoadjuvant therapy is increasingly used across oncology, and the ability to predict pathological response non-invasively, mid-treatment, could transform decision-making for many cancers. In sarcoma specifically, patients who respond well might be candidates for less radical surgery, preserving limbs and function, while non-responders could be escalated to alternative regimens before precious months are lost. The pharmacokinetic parameters underlying the habitat approach are mechanistically meaningful, tied to perfusion, vessel permeability, and cell death, rather than being opaque statistical correlations. That biological grounding gives the method a plausibility that purely data-driven radiomics sometimes lacks, and it offers a window into the tumor microenvironment that no size measurement can provide.

Cautions remain, and the authors are candid about them. Twenty-eight patients is a small sample, the responder group contained only five individuals, and the optimism-corrected performance figures show how much apparent accuracy can evaporate under validation. Treatment protocols were not fully standardized across the cohort, and the models have not yet been tested on external data. The researchers themselves call for validation in larger prospective multicenter cohorts with more balanced response groups and standardized treatment regimens. Yet as a proof of concept, the study is compelling: it demonstrates that the internal architecture of a tumor, read through the lens of DCE-MRI habitat imaging, carries early signals of treatment success that conventional imaging simply cannot see. If larger trials confirm these findings, the six-week MRI scan could become a routine checkpoint in sarcoma care, giving patients and physicians the one thing they currently lack, which is time to change course.

Subject of Research: DCE-MRI-based habitat imaging for early prediction of treatment response in soft tissue sarcoma

Article Title: Longitudinal DCE-MRI-based habitat imaging for early prediction of treatment response to neoadjuvant radiotherapy and targeted therapy in soft tissue sarcoma: a preliminary study

Article References: Jiang, X., Wen, X., Jiang, J., Liu, F., Yang, Z., Miao, L., Li, J., Wang, S., Li, M., & Lu, N. (2026). Longitudinal DCE-MRI-based habitat imaging for early prediction of treatment response to neoadjuvant radiotherapy and targeted therapy in soft tissue sarcoma: a preliminary study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02810-5

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02810-5

Keywords: soft tissue sarcoma, DCE-MRI, habitat imaging, radiomics, neoadjuvant radiotherapy, treatment response, Ktrans, Tofts model, RECIST 1.1, pathological response, machine learning, biomarker